Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 4/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397493 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL6767466 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL2452698 | 0.89 | HTR2C (0.37) | HTR2CCHRNB2CHRNA4PNMT | |
| SCHEMBL2342848 | 0.86 | CHRNB2 (0.48) | HTR2CCHRNB2CHRNA4CHRM4CHRM5 | |
| SCHEMBL29772412 | 0.84 | POLB (0.43) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL160968 | 0.84 | POLB (0.43) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL6438259 | 0.84 | CHRNB2 (0.47) | HTR2CCHRNB2CHRNA4CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL31126075 | 0.82 | POLB (0.42) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL7009520 | 0.82 | POLB (0.42) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL1195270 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | claimed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| CN-120152721-A | Treatment of familial adenomatous polyposis with 13-membered macrolides | 齐卡尼治疗股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119768404-A | Heteroaryl substituted pyridopyrrolidone derivatives, pharmaceutical compositions and uses thereof | 上海海雁医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4511375-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-116157400-B | Heterocyclic derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-4077312-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022206724-A1 | HETEROCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220218734-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA | UNIV GENT (BE) | 2022-07-14 | — | — | US | disclosed |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| CN-114269735-A | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | 南京创济生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | HTR2C 503/4885CHRNB2 3262/4885CHRNA4 3990/4885 |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4531/4885CHRNB2 4879/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.